000			01745 a2200481 4500
005			20250516101042.0
264		0	_c20121102
008			201211s 0 0 eng d
022			_a1555-7162
024	7		_a10.1016/j.amjmed.2011.12.002 _2doi
040			_aNLM _beng _cNLM
100	1		_aVieweg, W Victor R
245	0	0	_aCitalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? _h[electronic resource]
260			_bThe American journal of medicine _cSep 2012
300			_a859-68 p. _bdigital
500			_aPublication Type: Case Reports; Journal Article; Review
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntidepressive Agents, Second-Generation _xadministration & dosage
650	0	4	_aCitalopram _xadministration & dosage
650	0	4	_aDeath, Sudden, Cardiac _xetiology
650	0	4	_aDrug and Narcotic Control
650	0	4	_aFemale
650	0	4	_aHeart Ventricles _xdrug effects
650	0	4	_aHumans
650	0	4	_aLong QT Syndrome _xchemically induced
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aRisk Factors
650	0	4	_aSelective Serotonin Reuptake Inhibitors _xadministration & dosage
650	0	4	_aTorsades de Pointes _xchemically induced
650	0	4	_aUnited States
650	0	4	_aUnited States Food and Drug Administration
700	1		_aHasnain, Mehrul
700	1		_aHowland, Robert H
700	1		_aHettema, John M
700	1		_aKogut, Christopher
700	1		_aWood, Mark A
700	1		_aPandurangi, Ananda K
773	0		_tThe American journal of medicine _gvol. 125 _gno. 9 _gp. 859-68
856	4	0	_uhttps://doi.org/10.1016/j.amjmed.2011.12.002 _zAvailable from publisher's website
999			_c21907958 _d21907958